The clinical toxicology of gamma-hydroxybutyrate, gamma-butyrolactone and 1,4-butanediol

Clinical Toxicology

Volumn 50, Issue 6, 2012, Pages 458-470

  Schep, Leo J ^a   Knudsen, Kai ^b   Slaughter, Robin J ^a   Vale, J Allister ^c,d   Mégarbane, Bruno ^e  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^c CITY HOSPITAL   (United Kingdom)

^d UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^e HÔPITAL LARIBOISIÈRE   (France)

Author keywords

1,4 butanediol; CNS Psychological; Complications of poisoning; Gamma hydroxybutyrate; Gamma butyrolactone; Organ tissue specific; Pharmaceuticals

Indexed keywords

1,4 BUTANEDIOL; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID B RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID B RECEPTOR STIMULATING AGENT; 4 HYDROXYBUTYRIC ACID; 5,5 DIMETHYL 2 MORPHOLINEACETIC ACID; ACTIVATED CARBON; ANTIDOTE; ATROPINE; BACLOFEN; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARBAMAZEPINE; CHLORAL HYDRATE; CLONIDINE; DIAZEPAM; FLUMAZENIL; GABAPENTIN; GAMMA BUTYROLACTONE; GROWTH HORMONE; LORAZEPAM; NALOXONE; PAROXETINE; PHENOBARBITAL; PHYSOSTIGMINE; PROPOFOL; RECREATIONAL DRUG; VALPROIC ACID;

ANALYTIC METHOD; ARTIFICIAL VENTILATION; BLOOD BRAIN BARRIER; BRADYCARDIA; CARDIOTOXICITY; CENTRAL NERVOUS SYSTEM; CLINICAL PRACTICE; DRUG ABUSE; DRUG BLOOD LEVEL; DRUG CHOICE; DRUG EFFECT; DRUG ELIMINATION; DRUG HALF LIFE; DRUG INDICATION; DRUG INTOXICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG OVERDOSE; DRUG STRUCTURE; DRUG URINE LEVEL; DRUG WITHDRAWAL; ELECTROENCEPHALOGRAM; GAS CHROMATOGRAPHY; GASTROINTESTINAL SYMPTOM; GROWTH HORMONE RELEASE; HUMAN; HYPOTHERMIA; INTENSIVE CARE UNIT; INTUBATION; LIQUID CHROMATOGRAPHY; LIVER METABOLISM; MASS SPECTROMETRY; MYOCLONUS; NEUROTOXICITY; NEUROTRANSMITTER RELEASE; NONHUMAN; PATIENT MONITORING; POISON CENTER; PRACTICE GUIDELINE; RESPIRATION DEPRESSION; REVIEW; SEIZURE; SPECTROPHOTOMETRY; TOXICOKINETICS; WITHDRAWAL SYNDROME;

4-BUTYROLACTONE; ANTIDOTES; BUTYLENE GLYCOLS; CHARCOAL; HUMANS; SODIUM OXYBATE; SUBSTANCE WITHDRAWAL SYNDROME; THERAPEUTIC IRRIGATION; TISSUE DISTRIBUTION;

EID: 84863469235     PISSN: 15563650     EISSN: 15569519     Source Type: Journal    
DOI: 10.3109/15563650.2012.702218     Document Type: Review

References (231)

1. Rubin BA, Giarman NJ. The therapy of experimental inf uenza in mice with antibiotic lactones and related compounds. Yale J Biol Med 1947; 19:1017-1022.
2. Giacomino NJ, Mc CE. On the toxic reactions of unsaturated lactones and their saturated analogs. Fed Proc 1947; 6:331.
3. Laborit H, Jouany JM, Gerard J, Fabiani F. Summary of an experimental and clinical study on a metabolic substrate with inhibitory central action: sodium 4-hydroxybutyrate. Presse Med 1960; 68:1867-1869.
4. Dekkers MPJ. Le glycol tétraméthylénique. Recl Trav Chim Pays Bas 1890; 9:92-102.
5. Bessman SP, Fishbein WN. Gamma-hydroxybutyrate, a normal brain metabolite. Nature 1963; 200:1207-1208.
6. Blumenfeld M, Harmel MH, Suntay RG. Sodium gamma-hydroxybutyric acid: a new anesthetic adjuvant. Anesth Analg 1962; 41:721-726.
7. Solway J, Sadove MS. 4-Hydroxybutyrate: a clinical study. Anesth Analg 1965; 44:532-539.
8. Wedin GP, Hornfeldt CS, Ylitalo LM. The clinical development of gamma-hydroxybutyrate (GHB). Curr Drug Saf 2006; 1:99-106.
9. Takahara J, Yunoki S, Yakushiji W, Yamauchi J, Yamane Y, Ofuji T. Stimulatory effects of gamma-hydroxybutyric acid on growth hormone and prolactin release in humans. J Clin Endocrinol Metab 1977; 44:1014-1017.
10. Marwick C. Coma-inducing drug GHB may be reclassifed. JAMA 1997; 227:1505-1506.
11. Nelson LS. Butanediol and ethanol: a reverse mickey f nn? Int J Med Toxicol 2000; 3:2.
12. Rambourg-Schepens MO, Buffet M, Durak C, Mathieu-Nolf M. Gamma-butyrolactone poisoning and its similarities to gamma-hydroxybutyric acid: two case reports. Vet Hum Toxicol 1997; 39:234-235.
13. Knudsen K, Greter J, Verdicchio M, Cederquist T. GHB, GBL and butanediol poisonings\a serious problem in Western Sweden. Lakartidningen 2005; 102:3294-3296.
14. Knudsen K, Greter J, Verdicchio M. High mortality rates among GHB abusers in Western Sweden. Clin Toxicol (Phila) 2008; 46:187-192.
15. Knudsen K, Jonsson U, Abrahamsson J. Twenty-three deaths with gamma-hydroxybutyrate overdose in western Sweden between 2000 and 2007. Acta Anaesthesiol Scand 2010; 54:987-992.
16. Wood DM, Nicolaou M, Dargan PI. Epidemiology of recreational drug toxicity in a nightclub environment. Subst Use Misuse 2009; 44:1495-1502.
17. Liechti ME, Kupferschmidt H. Gamma-hydroxybutyrate (GHB) and gamma-butyrolactone (GBL): analysis of overdose cases reported to the Swiss Toxicological Information Centre. Swiss Med Wkly 2004; 134:534-537.
18. Rodgers J, Ashton CH, Gilvarry E,Young AH. Liquid ecstasy: a new kid on the dance foor. Br J Psychiatry 2004; 184:104-106.
19. Miró O, Nogué S, Espinosa G, To-Figueras J, Sánchez M. Trends in illicit drug emergencies: the emerging role of gamma- hydroxybutyrate. J Toxicol Clin Toxicol 2002; 40:129-135.
20. Liechti ME, Kunz I, Greminger P, Speich R, Kupferschmidt H. Clinical features of gamma-hydroxybutyrate and gamma-butyrolac-tone toxicity and concomitant drug and alcohol use. Drug Alcohol Depend 2006; 81:323-326.
21. Camacho A, Matthews SC, Murray B, Dimsdale JE. Use of GHB compounds among college students. Am J Drug Alcohol Abuse 2005; 31:601-607.
22. Degenhardt L, Darke S, Dillon P. GHB use among Australians: characteristics, use patterns and associated harm. Drug Alcohol Depend 2002; 67:89-94.
23. Degenhardt L, Copeland J, Dillon P. Recent trends in the use of "club drugs": an Australian review. Subst Use Misuse 2005; 40:1241-1256.
24. Harraway T, Stephenson L. Gamma hydroxybutyrate intoxication: the gold coast experience. Emerg Med (Fremantle) 1999; 11:45-48.
25. Dietze PM, Cvetkovski S, Barratt MJ, Clemens S. Patterns and incidence of gamma-hydroxybutyrate (GHB)-related ambulance attendances in Melbourne, Victoria. Med J Aust 2008; 188:709-711.
26. Robinson GM, Wardell JA. Gamma hydroxybutyric acid "fantasy"- drug of abuse. N Z Med J 2000; 113:65.
27. Theron L, Jansen K, Skinner A. New Zealand's f rst fatality linked to use of 1,4-butanediol (1,4-B, Fantasy): no evidence of coingestion or comorbidity. N Z Med J 2003; 116:U650.
28. Theron L, Jansen K, Miles J. Benzylpiperizine-based party pills' impact on the Auckland City Hospital Emergency Department Overdose Database (2002-2004) compared with ecstasy (MDMA or methylene dioxymethamphetamine), gamma hydroxybutyrate (GHB), amphetamines, cocaine, and alcohol. N Z Med J 2007; 120:U2416.
29. Couper FJ, Thatcher JE, Logan BK. Suspected GHB overdoses in the emergency department. J Anal Toxicol 2004; 28:481-484.
30. Louagie HK, Verstraete AG, DeSoete CJ, Baetens DG, Calle PA. A sudden awakening from a near coma after combined intake of gamma-hydroxybutyric acid (GHB) and ethanol. J Toxicol Clin Toxicol 1997; 35:591-594.
31. Li J, Stokes SA, Woeckener A. A tale of novel intoxication: seven cases of gamma-hydroxybutyric acid overdose. Ann Emerg Med 1998; 31:723-728.
32. Chin RL, Sporer KA, Cullison B, Dyer JE, Wu TD. Clinical course of gamma-hydroxybutyrate overdose. Ann Emerg Med 1998; 31:716-722.
33. Van Sassenbroeck DK, De Neve N, De Paepe P, Belpaire FM, Ver-straete AG, Calle PA, Buylaert WA. Abrupt awakening phenomenon associated with gamma-hydroxybutyrate use: a case series. Clin Toxicol (Phila) 2007; 45:533-538.
34. Miotto K, Darakjian J, Basch J, Murray S, Zogg J, Rawson R. Gam-ma-hydroxybutyric acid: patterns of use, effects and withdrawal. Am J Addict 2001; 10:232-241.
35. Roberts DM, Smith MW, Gopalakrishnan M, Whittaker G, Day RO. Extreme gamma-butyrolactone overdose with severe metabolic aci-dosis requiring hemodialysis. Ann Emerg Med 2011; 58:83-85.
36. Munir VL, Hutton JE, Harney JP, Buykx P, Weiland TJ, Dent AW. Gamma-hydroxybutyrate: a 30 month emergency department review. Emerg Med Australas 2008; 20:521-530.
37. Wood DM, Warren-Gash C, Ashraf T, Greene SL, Shather Z, Trivedy C, et al. Medical and legal confusion surrounding gamma-hydroxybutyrate (GHB) and its precursors gamma-butyrolactone (GBL) and 1,4-butanediol (1,4BD). QJM 2008; 101:23-29.
38. Galicia M, Nogue S, Miro O. Liquid ecstasy intoxication: clinical features of 505 consecutive emergency department patients. Emerg Med J 2011; 28:462-466.
39. Anderson IB, Kim SY, Dyer JE, Burkhardt CB, Iknoian JC, Walsh MJ, Blanc PD. Trends in gamma-hydroxybutyrate (GHB) and related drug intoxication: 1999 to 2003. Ann Emerg Med 2006; 47: 177-183.
40. Snead OC, Gibson KM. Gamma-hydroxybutyric acid. N Engl J Med 2005; 352:2721-2732.
41. Ryan JM, Stell I. Gamma hydroxybutyrate\a coma inducing recreational drug. J Accid Emerg Med 1997; 14:259-291.
42. Centers for Disease Control and Prevention (CDC). Gamma hydroxy butyrate use\New York and Texas, 1995-1996. MMWR Morb Mortal Wkly Rep 1997; 46:281-283.
43. Schneidereit T, Burkhart K, Donovan JW. Butanediol toxicity delayed by preingestion of ethanol. Int J Med Toxicol 2000; 3:1.
44. Garrison G, Mueller P. Clinical features and outcomes after unintentional gamma hydroxybutyrate (GHB) overdose [abstract]. J Toxicol Clin Toxicol 1998; 35:503-504.
45. Stephens BG, Baselt RC. Driving under the inf uence of GHB? J Anal Toxicol 1994; 18:357-358.
46. Eckstein M, Henderson SO, DelaCruz P, Newton E. Gamma hy-droxybutyrate (GHB): report of a mass intoxication and review of the literature. Prehosp Emerg Care 1999; 3:357-361.
47. Bosman IJ, Lusthof KJ. Forensic cases involving the use of GHB in The Netherlands. Forensic Sci Int 2003; 133:17-21.
48. Ferrara SD, Tedeschi L, Frison G, Rossi A. Fatality due to gamma-hydroxybutyric acid (GHB) and heroin intoxication. J Forensic Sci 1995; 40:501-504.
49. ElSohly MA, Salamone SJ. Prevalence of drugs used in cases of alleged sexual assault. J Anal Toxicol 1999; 23:141-146.
50. Hindmarch I, Brinkmann R. Trends in the use of alcohol and other drugs in cases of sexual assault. Hum Psychopharmacol Clin Exp 1999; 14:225-231.
51. Slaughter L. Involvement of drugs in sexual assault. J Reprod Med 2000; 45:425-430.
52. Hindmarch I, ElSohly M, Gambles J, Salamone S. Forensic urinaly-sis of drug use in cases of alleged sexual assault. J Clin Forensic Med 2001; 8:197-205.
53. Scott-Ham M, Burton FC. Toxicological f ndings in cases of alleged drug-facilitated sexual assault in the United Kingdom over a 3-year period. J Clin Forensic Med 2005; 12:175-186.
54. Németh Z, Kun B, Demetrovics Z. The involvement of gamma-hydroxybutyrate in reported sexual assaults: a systematic review. J Psychopharmacol 2010; 24:1281-1287.
55. Fuller DE, Hornfeldt CS. From club drug to orphan drug: sodium oxybate (Xyrem) for the treatment of cataplexy. Pharmacotherapy 2003; 23:1205-1209.
56. Caputo F, Vignoli T, Maremmani I, Bernardi M, Zoli G. Gamma hy-droxybutyric acid (GHB) for the treatment of alcohol dependence: a review. Int J Environ Res Public Health 2009; 6:1917-1929.
57. UNODC. World Drug Report. Vienna, Austria: United Nations Off ce on Drugs and Crime; 2011. http://www.unodc.org/documents/data-and-analysis/WDR2011/ World-Drug-Report-2011-ebook. pdf. Accessed 18 April 2012. Vienna, Austria; 2011.
58. EMCDDA. GHB and its precursor GBL: an emerging trend case study. Thematic papers, European Monitoring Centre for Drugs and Drug Addiction. Available at: http://www.emcdda.europa.eu/publications/thematic-papers/ghb. Accessed 18 April 2012. Lisbon; 2008.
59. UNODC. Global Smart update, Volume 3: United Nations Off ce on Drugs and Crime; 2011. http://www.unodc.org/documents/scientif c/Global-SMART-Update-2010- Vol.3-LowRes.pdf. Accessed 18 April 2012. Vienna, Austria; 2010.
60. ACC. Austrailan Crime Commission. Ilicit Drug Data Report (2010-2011). Available at: http://www.crimecommission.gov.au/publications/illicit-drug-data- report/illicit-drug-data-report-2010-11. Accessed 18 May 2012. Canberra City, Australia, 2011.
61. AIHW. Australian Institute of Health and Welfare: National Drug Strategy Household Survey report. Drug statistics series no. 25. Canberra, Australia; 2011.
62. Watson WA, Litovitz TL, Rodgers GC, Klein-Schwartz W, Youniss J, Rose SR, et al. 2002 annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med 2003; 21:353-421.
63. Bronstein AC, Spyker DA, Cantilena LR, Green JL, Rumack BH, Dart RC. 2010 Annual Report of the American Association of Poison Control Centers ' National Poison Data System (NPDS): 28th Annual Report (Supplementary material). Clin Toxicol (Phila) 2011; 49:910-941.
64. Doherty JD, Hattox SE, Snead OC, Roth RH. Identif cation of endogenous gamma-hydroxybutyrate in human and bovine brain and its regional distribution in human, guinea-pig and rhesus-monkey brain. J Pharmacol Exp Ther 1978; 207:130-139.
65. Roth RH, Giarman NJ. Natural occurrence of gamma-hydroxybutyrate in mammalian brain. Biochem Pharmacol 1970; 19:1087-1093.
66. Maitre M. The gamma-hydroxybutyrate signalling system in brain: organization and functional implications. Prog Neurobiol 1997; 51:337-361.
67. Hechler V, Weissmann D, Mach E, Pujol JF, Maitre M. Regional distribution of high-aff nity gamma-[H-3] hydroxybutyrate binding-sites as determined by quantitative autoradiography. J Neurochem 1987; 49:1025-1032.
68. Hechler V, Gobaille S, Maitre M. Selective distribution pattern of gamma-hydroxybutyrate receptors in the rat forebrain and mid-brain as revealed by quantitative autoradiography. Brain Res 1992; 572:345-348.
69. Castelli MP, Mocci I, Langlois X, Gommeren W, Luyten W, Leysen JE, Gessa GL. Quantitative autoradiographic distribution of gamma-hydroxybutyric acid binding sites in human and monkey brain. Brain Res Mol Brain Res 2000; 78:91-99.
70. Snead OC. Evidence for a G protein-coupled gamma-hydroxybutyr-ic acid receptor. J Neurochem 2000; 75:1986-1996.
71. Hu RQ, Banerjee PK, Snead OC. Regulation of gamma-aminobutyr-ic acid (GABA) release in cerebral cortex in the gamma-hydroxybu-tyric acid (GHB) model of absence seizures in rat. Neuropharmacol-ogy 2000; 39:427-439.
72. Howard SG, Feigenbaum JJ. Effect of gamma-hydroxybutyrate on central dopamine release in vivo. A microdialysis study in awake and anesthetized animals. Biochem Pharmacol 1997; 53:103-10.
73. Hechler V, Gobaille S, Bourguignon JJ, Maitre M. Extracellular events induced by gamma-hydroxybutyrate in striatum: a microdi-alysis study. J Neurochem 1991; 56:938-944.
74. Hedner T, Lundborg P. Effect of gammahydroxybutyric acid on serotonin synthesis, concentration and metabolism in the developing rat brain. J Neural Transm 1983; 57:39-48.
75. Lason W, Przewlocka B, Przewlocki R. The effect of gamma-hydroxybutyrate and anticonvulsants on opioid peptide content in the rat brain. Life Sci 1983; 33 Suppl 1:599-602.
76. Gerra G, Caccavari R, Fontanesi B, Marcato A, Fertonani Affni G, Maestri D, et al. Flumazenil effects on growth hormone response to gamma-hydroxybutyric acid. Int Clin Psychopharmacol 1994; 9:211-215.
77. Addolorato G, Capristo E, Gessa GL, Caputo F, Stefanini GF, Gas-barrini G. Long-term administration of GHB does not affect muscular mass in alcoholics. Life Sci 1999; 65:PL191-PL196.
78. Snead OC. The gamma-hydroxybutyrate model of absence seizures: correlation of regional brain levels of gamma-hydroxybutyric acid and gamma-butyrolactone with spike wave discharges. Neurophar-macology 1991; 30:161-167.
79. Williams SR, Turner JP, Crunelli V. Gamma-hydroxybutyrate promotes oscillatory activity of rat and cat thalamocortical neurons by a tonic GABAB, receptor-mediated hyperpolarization. Neuroscience 1995; 66:133-141.
80. Palatini P, Tedeschi L, Frison G, Padrini R, Zordan R, Orlando R, et al. Dose-dependent absorption and elimination of gamma-hydroxybutyric acid in healthy volunteers. Eur J Clin Pharmacol 1993; 45:353-356.
81. Borgen LA, Okerholm R, Morrison D, Lai A. The inf uence of gender and food on the pharmacokinetics of sodium oxybate oral solution in healthy subjects. J Clin Pharmacol 2003;43:59-65.
82. Brenneisen R, Elsohly MA, Murphy TP, Passarelli J, Russmann S, Salamone SJ, Watson DE. Pharmacokinetics and excretion of gamma-hydroxybutyrate (GHB) in healthy subjects. J Anal Toxicol 2004; 28:625-630.
83. Helrich M, Mcaslan TC, Skolnik S, Bessman SP. Correlation of blood levels of 4-hydroxybutyrate with state of consciousness. Anesthesiology 1964; 25:771-775.
84. Abanades S, Farre M, Segura M, Pichini S, Barral D, Pacifci R, et al. Gamma-hydroxybutyrate (GHB) in humans: pharmacodynam-ics and pharmacokinetics. Ann N Y Acad Sci 2006; 1074:559-576.
85. Scharf MB, Lai AA, Branigan B, Stover R, Berkowitz DB. Pharma-cokinetics of gammahydroxybutyrate (GHB) in narcoleptic patients. Sleep 1998; 21:507-514.
86. Borgen LA, Okerholm RA, Lai A, Scharf MB. The pharmacokinetics of sodium oxybate oral solution following acute and chronic administration to narcoleptic patients. J Clin Pharmacol 2004; 44:253-257.
87. Ferrara SD, Zotti S, Tedeschi L, Frison G, Castagna F, Gallimberti L, et al. Pharmacokinetics of gamma-hydroxybutyric acid in alcohol dependent patients after single and repeated oral doses. Br J Clin Pharmacol 1992; 34:231-235.
88. Ferrara SD, Tedeschi L, Frison G, Orlando R, Mazzo M, Zordan R, et al. Effect of moderate or severe liver dysfunction on the phar-macokinetics of gamma-hydroxybutyric acid. Eur J Clin Pharmacol 1996; 50:305-310.
89. Thai D, Dyer JE, Jacob P, Haller CA. Clinical pharmacology of 1,4-butanediol and gamma-hydroxybutyrate after oral 1,4-butanediol administration to healthy volunteers. Clin Pharmacol Ther 2007; 81:178-184.
90. Hoes MJ, Vree TB, Guelen PJ. Gamma-hydroxybutyric acid as hypnotic. Clinical and pharmacokinetic evaluation of gamma-hydroxybutyric acid as hypnotic in man. Encephale 1980; 6:93-100.
91. Metcalf DR, Emde RN, Stripe JT. An EEG-behavioral study of sodium hydroxybutyrate in humans. Electroencephalogr Clin Neuro-physiol 1966; 20:506-512.
92. Vree TB, Damsma J, van den Bogert AG, van den Kleijn E. Phar-mocokinetics of 4-hydroxybutyric acid in man, rhesus monkey and dog. In: Frey R, ed. Neue Untersuchungen mit Gamma-Hydroxy-buttersäure. Berlin: Springer-Verlag; 1978:21-39.
93. Lettieri JT, Fung HL. Dose-dependent pharmacokinetics and hypnotic effects of sodium gamma-hydroxybutyrate in the rat. J Pharmacol Exp Ther 1979; 208:7-11.
94. Lettieri J, Fung HL. Absorption and f rst-pass metabolism of 14C-gamma-hydroxybutyric acid. Res Commun Chem Pathol Pharmacol 1976; 13:425-437.
95. Pol W, Kleijn E, Lauw M. Gas chromatographic determination and pharmacokinetics of 4-hydroxybutrate in dog and mouse. J Pharma-cokinet Biopharm 1975; 3:99-113.
96. van den Bogert AG, Vree TB, van den Kleijn E, Damsma J. Placen-tal transfer of 4-hydroxybutyric acid in man. In: Frey R, ed. Neue Untersuchungen mit Gamma-Hydroxybutters ä ure. Berlin: Springer-Verlag; 1978:55-65.
97. Tunstall ME. Placental transfer of 4-hydroxybutyrate. Anaesthesia 1968; 23:704-705.
98. Snead OC. Gamma-hydroxybutyrate. Life Sci 1977; 20:1935-1944.
99. Snead OC, Yu RK, Huttenlocher PR. Gamma hydroxybutyrate. Correlation of serum and cerebrospinal f uid levels with electroencephalo-graphic and behavioral effects. Neurology 1976; 26: 51-56.
100. Snead OC. Gamma hydroxybutyrate in the monkey. I. Electroen- cephalographic, behavioral, and pharmacokinetic studies. Neurology 1978; 28:636-642.
101. Bessman SP, Skolnik SJ. Gamma hydroxybutyrate and gamma butyrolactone: concentration in rat tissues during anesthesia. Science 1964; 143:1045-1047.
102. Chambliss KL, Gibson KM. Succinic semialdehyde dehydrogenase from mammalian brain: subunit analysis using polyclonal antiserum. Int J Biochem 1992; 24:1493-1499.
103. Vayer P, Mandel P, Maitre M. Conversion of gamma-hydroxybutyrate to gamma-aminobutyrate in vitro. J Neurochem 1985; 45:810-814.
104. Poldrugo F, Snead OC. 1,4-Butanediol and ethanol compete for degradation in rat brain and liver in vitro. Alcohol 1986; 3:367-370.
105. Quang LS, Desai MC, Shannon MW, Woolf AD, Maher TJ. 4-methylpyrazole decreases 1,4-butanediol toxicity by blocking its in vivo biotransformation to gamma-hydroxybutyric acid. Ann N Y Acad Sci 2004; 1025:528-537.
106. Mégarbane B, Fompeydie D, Garnier R, Baud FJ. Treatment of a 1,4-butanediol poisoning with fomepizole. J Toxicol Clin Toxicol 2002; 40:77-80.
107. Roth RH, Giarman NJ. Preliminary report on the metabolism of gamma-butyrolactone and gamma-hydroxybutyric acid. Biochem Pharmacol 1965; 14:177-178.
108. Roth RH. Dependence of rat serum lactonase upon calcium. Bio-chem Pharmacol 1967; 16:596-598.
109. Arena C, Fung HL. Absorption of sodium gamma-hydroxybu-tyrate and its prodrug gamma-butyrolactone: relationship between in vitro transport and in vivo absorption. J Pharm Sci 1980; 69:356-358.
110. Centers for Disease Control (CDC). Multistate outbreak of poisonings associated with illicit use of gamma hydroxy butyrate. MMWR Morb Mortal Wkly Rep 1990; 39:861-863.
111. Li J, Stokes SA, Woeckener A. A tale of novel intoxication: a review of the effects of gamma-hydroxybutyric acid with recommendations for management. Ann Emerg Med 1998; 31:729-736.
112. Vickers MD. Gammahydroxybutyric acid. Int Anesthesiol Clin 1969; 7:75-89.
113. Galloway GP, Frederick SL, Staggers FE, Gonzales M, Stalcup SA, Smith DE. Gamma-hydroxybutyrate: an emerging drug of abuse that causes physical dependence. Addiction 1997; 92:89-96.
114. Piastra M, Tempera A, Caresta E, Chiaretti A, Genovese O, Zorzi G, et al. Lung injury from " liquid ecstasy ": a role for coagulation activation? Pediatr Emerg Care 2006; 22:358-360.
115. Al-Samarraie MS, Karinen R, Morland J, Opdal MS. Blood GHB concentrations and results of medical examinations in 25 car drivers in Norway. Eur J Clin Pharmacol 2010; 66:987-998.
116. Gunja N, Doyle E, Carpenter K, Chan OT, Gilmore S, Browne G, Graudins A. Gamma-hydroxybutyrate poisoning from toy beads. Med JAust 2008; 188:54-55.
117. Hefele B, Naumann N, Trollmann R, Dittrich K, Rascher W. Fast-in, fast-out. Lancet 2009; 373:1398.
118. Ragg M. Gamma hydroxy butyrate overdose. Emerg Med (Fremantle) 1997; 9:29-31.
119. Ross TM. Gamma hydroxybutyrate overdose: two cases illustrate the unique aspects of this dangerous recreational drug. J Emerg Nurs 1995; 21:374-376.
120. Zvosec DL, Smith SW, McCutcheon JR, Spillane J, Hall BJ, Peacock EA. Adverse events, including death, associated with the use of 1,4-butanediol. N Engl J Med 2001; 344:87-94.
121. Ortmann LA, Jaeger MW, James LP, Schexnayder SM. Coma in a 20-month-old child from an ingestion of a toy containing 1,4-butanediol, a precursor of gamma-hydroxybutyrate. Pediatr Emerg Care 2009; 25:758-760.
122. Ingels M, Rangan C, Bellezzo J, Clark RF. Coma and respiratory depression following the ingestion of GHB and its precursors: three cases. J Emerg Med 2000; 19:47-50.
123. Williams H, Taylor R, Roberts M. Gamma-hydroxybutyrate (GHB): a new drug of misuse. Ir Med J 1998; 91:56-57.
124. Dyer JE. Gamma-hydroxybutyrate: a health-food product producing coma and seizurelike activity. Am J Emerg Med 1991; 9:321-324.
125. Chin MY, Kreutzer RA, Dyer JE. Acute poisoning from gamma-hydroxybutyrate in California. West J Med 1992; 156:380-384.
126. Viswanathan S, Chen C, Kolecki P. Revivarant (gamma-butyrola-ctone) poisoning. Am J Emerg Med 2000; 18:358-359.
127. Osterhoudt KC, Henretig FM. Comatose teenagers at a party: what a tangled 'Web' we weave. Pediatr Case Rev 2003; 3:171-173.
128. Shannon M, Quang LS. Gamma-hydroxybutyrate, gamma-butyrolactone, and 1,4-butanediol: a case report and review of the literature. Pediatr Emerg Care. 2000:16; 435-440.
129. Caldicott DG, Kuhn M. Gamma-hydroxybutyrate overdose and physostigmine: teaching new tricks to an old drug? Ann Emerg Med 2001; 37:99-102.
130. Runnacles JL, Stroobant J. [gamma]-Hydroxybutyrate poisoning: poisoning from toy beads. BMJ 2008; 336:110.
131. Price PA, Schachter M, Smith S, Baxter RC, Parkes JD. gamma-Hydroxybutyrate in narcolepsy. Ann Neurol 1981; 9:198.
132. Luby S, Jones J, ZalewskiA. GHB use in South Carolina.Am J Public Health 1992; 82:128.
133. Yates SW, Viera AJ. Physostigmine in the treatment of gamma-hydroxybutyric acid overdose. Mayo Clin Proc 2000; 75:401-402.
134. Libetta C. Gamma hydroxybutyrate poisoning. J Accid Emerg Med 1997; 14:411.
135. Savage T, Khan A, Loftus BG. Acetone-free nail polish remover pads: toxicity in a 9-month old. Arch Dis Child 2007; 92:371.
136. Centers for Disease Control and Prevention (CDC). Adverse events associated with ingestion of gamma-butyrolactone\Minnesota, New Mexico, and Texas 1998-1999. MMWR Morb Mortal Wkly Rep. 1999: 48; 137-140.
137. Robert R, Eugène M, Frat JP, Rouffneau J. Diagnosis of unsuspected gamma hydroxy-butyrate poisoning by proton NMR. J Toxicol Clin Toxicol 2001; 39:653-654.
138. Winickoff JP, Houck CS, Rothman EL, Bauchner H. Verve and jolt: deadly new Internet drugs. Pediatrics 2000; 106:829-831.
139. Lenz D, Rothschild MA, Kroner L. Intoxications due to ingestion of gamma-butyrolactone: organ distribution of gamma-hydroxy-butyric acid and gamma-butyrolactone. Ther Drug Monit 2008;30: 755-761.
140. Lora-Tamayo C, Tena T, Rodriguez A, Sancho JR, Molina E. Intoxication due to 1,4-butanediol. Forensic Sci Int 2003; 133: 256-259.
141. Higgins TFJ, Borron SW. Coma and respiratory arrest after exposure to butyrolactone. J Emerg Med 1996; 14:435-457.
142. Yambo CM, McFee RB, Caraccio TR, McGuigan M. The inkjet cleaner "Hurricane"-another GHB recipe. Vet Hum Toxicol 2004; 46:329-330.
143. Suner S, Szlatenyi CS, Wang RY. Pediatric gamma hydroxybutyrate intoxication. Acad Emerg Med 1997; 4:1041-1045.
144. Krul J, Girbes AR. Gamma-hydroxybutyrate: experience of 9 years of gamma-hydroxybutyrate (GHB)-related incidents during rave parties in The Netherlands. Clin Toxicol (Phila) 2011; 49:311-315.
145. Zvosec DL, Smith SW. Agitation is common in gamma-hydroxybutyrate toxicity. Am J Emerg Med 2005; 23:316-320.
146. Elliott S. Nonfatal instances of intoxication with gamma-hydroxybutyrate in the United Kingdom. Ther Drug Monit 2004; 26: 432-440.
147. Tancredi DN, Shannon MW. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 30-2003. A 21-year-old man with sudden alteration of mental status. N Engl J Med 2003; 349:1267-1275.
148. Cisek J. Seziure associated with Butanediol ingestion. Int J Med Toxicol 2001; 4:12.
149. Couper FJ, Logan BK. Determination of gamma-hydroxybutyrate (GHB) in biological specimens by gas chromatography\mass spec-trometry. J Anal Toxicol 2000;24:1-7.
150. Hardy CJ, Slifman NR, Klontz KC, Dyer JE, Coody GL, Love LA. Adverse events reported with the use of gamma butyrolactone products marketed as dietary supplements [abstract]. Clin Toxicol (Phila) 1999; 37:649-650.
151. Virtue RW, Lund LO, Beckwitt HJ, Vogel JH. Cardiovascular reactions to gamma hydroxybutyrate in man. Can Anaesth Soc J 1966; 13:119-123.
152. Geldenhuys FG, Sonnendecker EW, De Klrk MC. Experience with sodium-gamma-4-hydroxybutyric acid (gamma-OH) in obstetrics. J Obstet Gynaecol Br Commonw1968; 75:405-413.
153. Tunstall ME. Gamma-OH in anesthesia for caesarean section. Proc R Soc Med 1968; 61:827-830.
154. Hunter AS, Long WJ, Ryrie CG. An evaluation of gamma-hydroxybutyric acid in paediatric practice. Br J Anaesth 1971; 43:620-628.
155. Laborit H. Soduim 4-Hydroxybutyrate. Int J Neuropharmacol 1964; 3:433-451.
156. Piastra M, Barbaro R, Chiaretti A, Tempera A, Pulitanò S, Polidori G. Pulmonary oedema caused by "liquid ecstasy" ingestion. Arch Dis Child 2002; 86:302-303.
157. Jones C. Suspicious death related to gamma-hydroxybutyrate (GHB) toxicity. J Clin Forensic Med 2001; 8:74-76.
158. Brown TC. Gammahydroxybutyrate in paediatric anaesthesia. Aust N Z J Surg 1970; 40:94-99.
159. Win BH, Baselt RC. Apparent suicide with Renewtrient. J Toxicol Clin Toxicol 2000; 38:809.
160. Zvosec DL, Smith SW, Hall BJ. Three deaths associated with use of Xyrem. Sleep Med 2009; 10:490-493.
161. Zvosec DL, Smith SW, Porrata T, Strobl AQ, Dyer JE. Case series of 226 gamma-hydroxybutyrate-associated deaths: lethal toxicity and trauma. Am J Emerg Med 2011; 29:319-332.
162. Timby N, Eriksson A, Bostrom K. Gamma-hydroxybutyrate associated deaths. Am J Med 2000; 108:518-519.
163. Kugelberg FC, Holmgren A, Eklund A, Jones AW. Forensic toxicology f ndings in deaths involving gamma-hydroxybutyrate. Int J Legal Med 2010; 124:1-6.
164. Akins BE, Miranda E, Lacy JM, Logan BK. A multi-drug intoxication fatality involving Xyrem (GHB). J Forensic Sci 2009; 54: 495-496.
165. Caldicott DGE, Chow FY, Burns BJ, Felgate PE, Byard RW. Fatalities associated with the use of gamma-hydroxybutyrate and its analogues in Australasia. Med J Aust 2004; 181:310-313.
166. McCabe ER, Layne EC, Sayler DF, Slusher N, Bessman SP. Synergy of ethanol and a natural soporif c\gamma hydroxybu-tyrate. Science 1971; 171:404-406.
167. Lettieri JT, Fung HL. Evaluation and development of gas chromato-graphic procedures for the determination of gamma-hydroxybutyric acid and gamma-butyrolactone in plasma. Biochem Med 1978; 20:70-80.
168. Elian AA. GC-MS determination of gamma-hydroxybutyric acid (GHB) in blood. Forensic Sci Int 2001; 122:43-47.
169. McCusker RR, Paget-Wilkes H, Chronister CW, Goldberger BA. Analysis of gamma-hydroxybutyrate (GHB) in urine by gas chroma-tography-mass spectrometry. J Anal Toxicol 1999; 23:301-305.
170. Mesmer MZ, Satzger RD. Determination of Gamma-Hydroxybutyrate (GHB) and Gamma-Butyrolactone (GBL) by HPLC/UV-VIS Spectrophotometry and HPLC/Thermospray Mass Spectrometry. J Forensic Sci 1998; 43:489-492.
171. Marinetti LJ, Isenschmid DS, Hepler BR, Kanluen S. Analysis of GHB and 4-methyl-GHB in postmortem matrices after long-term storage. J Anal Toxicol 2005; 29:41-47.
172. Kintz P, Villain M, Cirimele V, Ludes B. GHB in postmortem toxicology. Discrimination between endogenous production from exposure using multiple specimens. Forensic Sci Int 2004; 143:177-181.
173. Jones AW, Holmgren A, Kugelberg FC. Gamma-hydroxybutyrate concentrations in the blood of impaired drivers, users of illicit drugs, and medical examiner cases. J Anal Toxicol 2007; 31:566-572.
174. Ferrara SD, Tedeschi L, Frison G, Castagna F, Gallimberti L, Giorgetti R, et al. Therapeutic gamma-hydroxybutyric acid monitoring in plasma and urine by gas chromatography-mass spectrometry. J Pharm Biomed Anal 1993; 11:483-487.
175. Quang LS. GHB and related compounds. In: Shannon MW, Borron SW, Burns MJ, eds. Haddad and Winchester's clinical management of poisoning and drug overdose. 4th ed. Philadelphia (PA): Saun-ders; 2007:803-823.
176. Elliott SP. Gamma hydroxybutyric acid (GHB) concentrations in humans and factors affecting endogenous production. Forensic Sci Int 2003; 133:9-16.
177. Elliott SP. Further evidence for the presence of GHB in postmortem biological f uid: implications for the interpretation of f ndings. J Anal Toxicol 2004; 28:20-26.
178. Elliott S. The presence of gamma-hydroxybutyric acid (GHB) in postmortem biological fuids. J Anal Toxicol 2001; 25:152.
179. LeBeau MA, Montgomery MA, Morris-Kukoski C, Schaff JE, Deakin A. Further evidence of in vitro production of gamma-hydroxybutyrate (GHB) in urine samples. Forensic Sci Int 2007; 169:152-156.
180. Chyka PA, Seger D, Krenzelok EP, Vale JA. Position paper: single dose activated charcoal. Clin Toxicol (Phila) 2005; 43:61-87.
181. Wood DM, Brailsford AD, Dargan PI. Acute toxicity and withdrawal syndromes related to gamma-hydroxybutyrate (GHB) and its analogues gamma-butyrolactone (GBL) and 1,4-butanediol (1,4-BD). Drug Test Anal 2011; 3:417-425.
182. Williams SR. Gamma-hydroxybutyric acid poisoning. West J Med 1998; 168:187-188.
183. Joint Formulary Committee. British National Formulary 59. London: Pharmaceutical Press; 2010.
184. Shah AS, Eddleston M. Should phenytoin or barbiturates be used as second-line anticonvulsant therapy for toxicological seizures? Clin Toxicol (Phila) 2010; 48:800-805.
185. Teter CJ, Guthrie SK.A comprehensive review of MDMA and GHB: two common club drugs. Pharmacotherapy 2001; 21:1486-1513.
186. Holmes CM, Henderson RS. The elimination of pollution by a non inhalational technique. Anaesth Intensive Care 1978; 6:120-124.
187. Traub SJ, Nelson LS, Hoffman RS. Physostigmine as a treatment for gamma-hydroxybutyrate toxicity: a review. J Toxicol Clin Toxicol 2002; 40:781-787.
188. Zvosec DL, Smith SW, Litonjua R, Westfal RE. Physostigmine for gamma-hydroxybutyrate coma: ineff cacy, adverse events, and review. Clin Toxicol (Phila) 2007; 45:261-265.
189. Persson B, Henning M. Central cardiovascular effects of gamma-hydroxybutyric acid: interactions with noradrenaline, serotonin, dopamine and acetylcholine transmission. Acta Pharmacol Toxicol (Copenh) 1980; 47:335-346.
190. Sethy VH, Roth RH, Walters JR, Marini J, Van Woert MH. Effect of anesthetic doses of gamma-hydroxybutyrate on the acetylcholine content of rat brain. Naunyn Schmiedebergs Arch Pharmacol 1976; 295:9-14.
191. Bania TC, Chu J. Physostigmine does not effect arousal but produces toxicity in an animal model of severe gamma-hydroxybutyrate intoxication. Acad Emerg Med 2005; 12:185-189.
192. Mullins ME, Dribben W. Physostigmine treatment of gamma-hy-droxybutyric acid overdose: appropriate or inappropriate use of a reversal agent? Mayo Clin Proc 2000; 75:871-872.
193. Boyer EW, Quang L, Woolf A, Shannon M. Use of physostigmine in the management of gamma-hydroxybutyrate overdose. Ann Emerg Med 2001; 38:346.
194. Feigenbaum JJ, Howard SG. Naloxone reverses the inhibitory effect of gamma-hydroxybutyrate on central DA release in vivo in awake animals: a microdialysis study. Neurosci Lett 1996; 218:5-8.
195. Devoto P, Colombo G, Cappai F, Gessa GL. Naloxone antagonizes ethanol-but not gamma-hydroxybutyrate-induced sleep in mice. Eur J Pharmacol 1994; 252:321-324.
196. Thomas G, Bonner S, Gascoigne A. Coma induced by abuse of gamma-hydroxybutyrate (GBH or liquid ecstasy): a case report. BMJ 1997; 314:35-36.
197. Lee DC, Satz WA, Dougherty T, Greene T. An investigation of f u-mazenil to antagonize gamma-hydroxybutyrate intoxication in a mu-rine model. J Med Toxicol 2006; 2:68-70.
198. Schmidt-Mutter C, Pain L, Sandner G, Gobaille S, Maitre M. The anxiolytic effect of gamma-hydroxybutyrate in the elevated plus maze is reversed by the benzodiazepine receptor antagonist, f uma-zenil. Eur J Pharmacol 1998; 342:21-27.
199. Carai MA, Colombo G, Quang LS, Maher TJ, Gessa GL. Resuscita-tive treatments on 1,4-butanediol mortality in mice. Ann Emerg Med 2006; 47:184-189.
200. Carai MA, Colombo G, Gessa GL. Resuscitative effect of a gamma-aminobutyric acid B receptor antagonist on gamma-hydroxybutyric acid mortality in mice. Ann Emerg Med 2005; 45:614-619.
201. Dyer JE, Roth B, Hyma BA. Gamma-hydroxybutyrate withdrawal syndrome. Ann Emerg Med 2001; 37:147-153.
202. Galloway GP, Frederick SL, Staggers F. Physical dependence on sodium oxybate. Lancet 1994; 343:57.
203. Wojtowicz JM, Yarema MC, Wax PM. Withdrawal from gamma-hydroxybutyrate, 1,4-butanediol and gamma-butyrolactone: a case report and systematic review. CJEM 2008; 10:69-74.
204. McDonough M, Kennedy N, Glasper A, Bearn J. Clinical features and management of gamma-hydroxybutyrate (GHB) withdrawal: a review. Drug Alcohol Depend 2004; 75:3-9.
205. van Noorden MS, van Dongen L, Zitman FG, Vergouwen T. Gamma-hydroxybutyrate withdrawal syndrome: dangerous but not well-known. Gen Hosp Psychiatry 2009; 31:394-396.
206. Miglani JS, Kim KY, Chahil R. Gamma-hydroxy butyrate withdrawal delirium: a case report. Gen Hosp Psychiatry 2000; 22:213-215.
207. Hutto B, Fairchild A, Bright R. Gamma-hydroxybutyrate withdrawal and chloral hydrate. Am J Psychiatry 2000; 157:1706.
208. Craig K, Gomez HF, McManus JL, Bania TC. Severe gamma-hydroxybutyrate withdrawal: a case report and literature review. J Emerg Med 2000; 18:65-70.
209. Gonzalez A, Nutt DJ. Gamma hydroxy butyrate abuse and dependency. J Psychopharmacol 2005; 19:195-204.
210. Hernandez M, McDaniel CH, Costanza CD, Hernandez OJ. GHB-induced delirium: a case report and review of the literature of gamma hydroxybutyric acid. Am J Drug Alcohol Abuse 1998; 24:179-183.
211. Catalano MC, Glass JM, Catalano G, Burrows SL, Lynn WA, Weitzner BS. Gamma butyrolactone (GBL) withdrawal syndromes. Psychosomatics 2001; 42:83-88.
212. Bowles TM, Sommi RW, Amiri M. Successful management of prolonged gamma-hydroxybutyrate and alcohol withdrawal. Pharmacotherapy 2001; 21:254-257.
213. Mahr G, Bishop CL, Orringer DJ. Prolonged withdrawal from extreme gamma-hydroxybutyrate (GHB) abuse. Psychosomatics 2001; 42:439-440.
214. McDaniel CH, Miotto KA. Gamma hydroxybutyrate (GHB) and gamma butyrolactone (GBL) withdrawal: f ve case studies. J Psy-choactive Drugs 2001; 33:143-149.
215. Schneir AB, Ly HT, Clark RF. A case of withdrawal from the GHB precursors gamma-butyrolactone and 1,4-butanediol. J Emerg Med 2001; 21:31-33.
216. Sivilotti MLA, Burns MJ, Aaron CK, Greenberg MJ. Pentobarbital for severe gamma-butyrolactone withdrawal. Ann Emerg Med 2001; 38:660-665.
217. Perez E, Chu J, Bania T. Seven days of gamma-hydroxybutyrate (GHB) use produces severe withdrawal. Ann Emerg Med 2006; 48:219-220.
218. Zepf FD, Holtmann M, Duketis E, Maier J, Radeloff D, Wagner A, et al. A 16-year-old boy with severe gamma-butyrolactone (GBL) withdrawal delirium. Pharmacopsychiatry 2009; 42: 202-203.
219. Bennett WRM, Wilson LG, Roy-Byrne PP. Gamma-hydroxybutyric acid (GHB) withdrawal: a case report. J Psychoactive Drugs 2007; 39:293-296.
220. Rosenberg MH, Deerfeld LJ, Baruch EM. Two cases of severe gamma-hydroxybutyrate withdrawal delirium on a psychiatric unit: recommendations for management. Am J Drug Alcohol Abuse 2003; 29:487-496.
221. Friedman J, Westlake R, Furman M. "Grievous bodily harm": gamma hydroxybutyrate abuse leading to a Wernicke-Korsakoff syndrome. Neurology 1996; 46:469-471.
222. Bell J, Collins R. Gamma-butyrolactone (GBL) dependence and withdrawal. Addiction 2011; 106:442-447.
223. Addolorato G, Caputo F, Capristo E, Bernardi IM, Stefanini GF, Gasbarrini G. A case of gamma-hydroxybutyric acid withdrawal syndrome during alcohol addiction treatment: utility of diazepam administration. Clin Neuropharmacol 1999; 22:60-62.
224. Mycyk MB, Wilemon C,Aks SE. Two cases of withdrawal from 1,4-Butanediol use. Ann Emerg Med 2001; 38:345-346.
225. Herold AH, Sneed KB. Treatment of a young adult taking gamma-butyrolactone (GBL) in a primary care clinic. J Am Board Fam Pract 2002; 15:161-163.
226. Chew G, Fernando A. Epileptic seizure in GHB withdrawal. Austra-las Psychiatry 2004; 12:410-411.
227. LeTourneau JL, Hagg DS, Smith SM. Baclofen and gamma-hydroxybutyrate withdrawal. Neurocrit Care 2008; 8:430-433.
228. Mullins ME, Fitzmaurice SC. Lack of eff cacy of benzodiazepines in treating gamma-hydroxybutyrate withdrawal. J Emerg Med 2001; 20:418-420.
229. Price G. In-patient detoxif cation after GHB dependence. Br J Psychiatry 2000; 177:181.
230. Dyer JE, Andrews KM. Gamma hydroxybutyrate withdrawal [abstract]. J Toxicol Clin Toxicol 1997; 35:553-554.
231. Maccioli GA. Dexmedetomidine to facilitate drug withdrawal. Anesthesiology 2003; 98:575-577.